BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eighteen brokerages that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $137.91.

A number of analysts have commented on BNTX shares. Citigroup reissued a "buy" rating and set a $140.00 price objective (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. The Goldman Sachs Group initiated coverage on BioNTech in a report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $138.00 target price on shares of BioNTech in a research note on Wednesday, June 25th. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, Leerink Partners set a $112.00 target price on BioNTech in a research note on Monday, June 2nd.

BioNTech Stock Down 0.5%

BNTX traded down $0.58 during midday trading on Thursday, reaching $113.34. 233,030 shares of the company were exchanged, compared to its average volume of 941,261. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The company's fifty day moving average price is $103.40 and its 200 day moving average price is $106.86. The company has a market cap of $27.25 billion, a price-to-earnings ratio of -33.30 and a beta of 1.29. BioNTech has a one year low of $76.53 and a one year high of $131.49.

Hedge Funds Weigh In On BioNTech

Several institutional investors have recently bought and sold shares of BNTX. FMR LLC lifted its position in shares of BioNTech by 22.2% during the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock worth $877,583,000 after acquiring an additional 1,401,547 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of BioNTech by 18,892.9% during the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after acquiring an additional 694,691 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of BioNTech during the fourth quarter worth $69,999,000. Invesco Ltd. lifted its position in shares of BioNTech by 643.7% during the first quarter. Invesco Ltd. now owns 645,142 shares of the company's stock worth $58,747,000 after acquiring an additional 558,389 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of BioNTech by 632.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after acquiring an additional 433,388 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.